Eikon Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Eikon Therapeutics, Inc. Common Stock (EIKN) has an Asset Resilience Ratio of 49.84% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EIKN total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Eikon Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Eikon Therapeutics, Inc. Common Stock (EIKN) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Eikon Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Eikon Therapeutics, Inc. Common Stock asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $388.56 Million | 49.84% |
| Total Liquid Assets | $388.56 Million | 49.84% |
Asset Resilience Insights
- Very High Liquidity: Eikon Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 49.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eikon Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Eikon Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Dyne Therapeutics Inc
NASDAQ:DYN |
Biotechnology | 20.28% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX |
Biotechnology | 0.00% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
Annual Asset Resilience Ratio for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Eikon Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.85% | $231.07 Million | $594.73 Million | +20.34pp |
| 2024-12-31 | 18.51% | $90.93 Million | $491.24 Million | -41.91pp |
| 2023-12-31 | 60.42% | $317.63 Million | $525.71 Million | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more